Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Pediatr. Dec 9, 2025; 14(4): 108897
Published online Dec 9, 2025. doi: 10.5409/wjcp.v14.i4.108897
Published online Dec 9, 2025. doi: 10.5409/wjcp.v14.i4.108897
Deficiency of anterior pituitary hormones in Noonan syndrome and its impact on response to growth hormone therapy
Rajdeep Basu, Soumil Bera, Sunetra Mondal, Sapan Shah, Kumar Swapnil, Roohi Nanda, Joydip Datta, Soumita Mandal, Soumik Goswami, Arjun Baidya, Nilanjan Sengupta, Department of Endocrinology, NRS Medical College and Hospital, Kolkata 700014, West Bengal, India
Author contributions: Mondal S was involved in formulating the design of the project and writing the first draft; Basu R, Bera S, Shah S, Swapnil K, Nanda R, and Datta J participated in the collection, analysis, and interpretation of data; Goswami S and Mandal S critically analyzed the data and edited the draft incorporating important intellectual content; Baidya A and Sengupta NS were involved in data verification, supervision of the entire project and revising the draft critically; All authors read and approved the final manuscript.
Institutional review board statement: The study was cleared by the institutional ethics committee, NRSMC/IEC/45/2021 dated September 22, 2021.
Informed consent statement: Informed consent was taken from all participants and their parents/Legal guardians.
Conflict-of-interest statement: None of the authors have any conflicts of interest to disclose.
STROBE statement: The authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.
Data sharing statement: Data related to the study can be availed from the corresponding author upon reasonable request by direct mail to sunetra59@gmail.com
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sunetra Mondal, DM, FRCP, MD, MRCP, Assistant Professor, Department of Endocrinology, NRS Medical College and Hospital, 138, AJC Bose Road, Kolkata 700014, West Bengal, India. sunetra59@gmail.com
Received: April 25, 2025
Revised: May 22, 2025
Accepted: August 4, 2025
Published online: December 9, 2025
Processing time: 189 Days and 22.1 Hours
Revised: May 22, 2025
Accepted: August 4, 2025
Published online: December 9, 2025
Processing time: 189 Days and 22.1 Hours
Core Tip
Core Tip: Noonan syndrome (NS) can be associated with combined pituitary hormone deficiency (CPHD) and/or isolated growth hormone (GH) deficiency. Hypoplasia of the pituitary gland may contribute to CPHD in NS. Patients with NS and CPHD have decreased height and bodyweight but can have a better response to recombinant GH therapy than patients with NS but without CPHD. Children having a PTPN11 mutation with low insulin-like-growth-factor 1 should be tested for cortisol and thyroid function at baseline to rule out CPHD. If there is a suspicion for CPHD, the patient should undergo periodic testing for cortisol and thyroid function while receiving GH.